Methods for treating ocular inflammatory diseases

• US 10,201,548 B2
• Filed: 03/06/2009
• Issued: 02/12/2019
• Est. Priority Date: 03/06/2009
• Status: Active Grant

• Current Assignee: Sun Pharmaceutical Industries Limited
• Original Assignee: Sun Pharma Global Fze (Sun Pharmaceutical Industries Limited)
• Inventors: Bowman, Lyle, Hosseini, Kamran
• Primary Examiner(s): Fay, Zohreh A
• Application Number:
  US12/399,729
• Publication Number:
  US 20100227842A1
• Time in Patent Office: 3,630 Days
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: G06F 11/261 by simulating additional hardware, e.g. fault simulation
• CPC Class Codes: G06F 11/3013 where the computing system is an embedded system, i.e. a combination of hardware and software dedicated to perform a certain function in mobile devices, printers, automotive or aircraft systems testing or monitoring of control systems or parts thereof G05B23/02
• CPC Class Codes: G06F 11/3457 Performance evaluation by simulation
• CPC Class Codes: G06F 11/3476 Data logging G06F11/14, G06F11/2205 take precedence
• CPC Class Codes: G06F 11/3636 by tracing the execution of the program
• CPC Class Codes: G06F 11/366 using diagnostics G06F11/0703 takes precedence

Abstract

A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.

Claims

1. A method of treating blepharitis having as its pathophysiological origin bacteria, the method comprising administering twice daily to the affected eye of a subject who has said blepharitis, for 14 days or more, a composition comprising an active ingredient consisting of about 0.1% by weight dexamethasone in an ophthalmically acceptable vehicle,

wherein the ophthalmically acceptable vehicle comprises an aqueous polymer suspension comprising a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and an initial viscosity in a range from about 1,000 to about 30,000 centipoises, and which gels on contact with tear fluid,

wherein the method does not comprise administration of an antibiotic.

2. The method of claim 1, wherein the carboxyl-containing polymer is polycarbophil.

3. The method of claim 2, wherein the ophthalmically acceptable vehicle comprises 0.9% by weight of polycarbophil, 0.2% by weight of Polaxamer 407, an osmolality adjusting agent, a buffer in an amount sufficient to adjust a pH of the ophthalmically acceptable vehicle to be in a range from 3 to 6.5, and a preservative.